IL236523B - Methods for producing antibody molecules with intra-target cross-sexual reactivity - Google Patents

Methods for producing antibody molecules with intra-target cross-sexual reactivity

Info

Publication number
IL236523B
IL236523B IL236523A IL23652314A IL236523B IL 236523 B IL236523 B IL 236523B IL 236523 A IL236523 A IL 236523A IL 23652314 A IL23652314 A IL 23652314A IL 236523 B IL236523 B IL 236523B
Authority
IL
Israel
Prior art keywords
intra
reactivity
inter
species
antibody molecules
Prior art date
Application number
IL236523A
Other languages
English (en)
Hebrew (he)
Other versions
IL236523A0 (en
Inventor
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Der Woning Sebastian Paul Van
Original Assignee
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Der Woning Sebastian Paul Van
Argenx Bvba
Argenx Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haard Johannes Joseph Wilhelmus De, Christophe Frederic Jerome Blanchetot, Der Woning Sebastian Paul Van, Argenx Bvba, Argenx Se filed Critical Haard Johannes Joseph Wilhelmus De
Publication of IL236523A0 publication Critical patent/IL236523A0/en
Publication of IL236523B publication Critical patent/IL236523B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL236523A 2012-08-31 2014-12-31 Methods for producing antibody molecules with intra-target cross-sexual reactivity IL236523B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (2)

Publication Number Publication Date
IL236523A0 IL236523A0 (en) 2015-02-26
IL236523B true IL236523B (en) 2018-12-31

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236523A IL236523B (en) 2012-08-31 2014-12-31 Methods for producing antibody molecules with intra-target cross-sexual reactivity

Country Status (10)

Country Link
US (1) US20150203840A1 (enExample)
EP (2) EP2977386A1 (enExample)
JP (1) JP6391574B2 (enExample)
CN (1) CN104583238A (enExample)
AU (2) AU2013310924B2 (enExample)
CA (1) CA2878712A1 (enExample)
DK (1) DK2890711T3 (enExample)
IL (1) IL236523B (enExample)
IN (1) IN2015DN00140A (enExample)
WO (1) WO2014033252A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2686347B1 (en) 2011-03-16 2018-05-02 argenx BVBA Antibodies to cd70
EA035550B1 (ru) 2013-08-01 2020-07-06 Юниверсите Католик Де Лувэн АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С КОМПЛЕКСОМ hGARP/TGF-B1, И ИХ ПРИМЕНЕНИЕ
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
CA3083660A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CN112004826B (zh) 2018-02-05 2024-06-14 自由大学基金会 反向激动性抗us28抗体
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
JP7789368B2 (ja) * 2020-05-29 2025-12-22 学校法人 久留米大学 炎症性腸疾患に対する治療用抗体
US20240382499A1 (en) 2021-01-15 2024-11-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760562B2 (en) * 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
WO2004041862A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
AU2004223837C1 (en) * 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
EP2163562B1 (en) * 2005-06-21 2013-09-18 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
MX2012006406A (es) * 2009-12-04 2012-07-25 Genentech Inc Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
BR112013012858B1 (pt) * 2010-11-24 2021-12-07 Lexicon Pharmaceuticals, Inc Anticorpo monoclonal que se liga a pectinacetilesterase de notum, composição farmacêutica, molécula de ácido nucleico, célula hospedeira e método para produzir o dito anticorpo

Also Published As

Publication number Publication date
US20150203840A1 (en) 2015-07-23
DK2890711T3 (en) 2017-02-27
JP6391574B2 (ja) 2018-09-26
AU2017204188A1 (en) 2017-07-13
AU2013310924A8 (en) 2015-04-30
AU2013310924A1 (en) 2015-01-29
EP2890711B1 (en) 2017-01-04
CN104583238A (zh) 2015-04-29
AU2013310924B2 (en) 2017-08-03
EP2977386A1 (en) 2016-01-27
WO2014033252A1 (en) 2014-03-06
EP2890711A1 (en) 2015-07-08
JP2015530087A (ja) 2015-10-15
IL236523A0 (en) 2015-02-26
CA2878712A1 (en) 2014-03-06
IN2015DN00140A (enExample) 2015-06-12

Similar Documents

Publication Publication Date Title
IL236523B (en) Methods for producing antibody molecules with intra-target cross-sexual reactivity
IL267225B (en) Bispecific igg4 antibodies are asymmetrically sequenced
IL263389B (en) A method for the production of modified 5-fluoro-1h-pyrazolopyridines
IL242649A (en) Purification process of monoclonal antibody
LT2794658T (lt) Bispecifinė antikūno molekulė
LT2718404T (lt) Skystų angliavandenilių gamybos būdas
IL232558B (en) A method for antibody purification
IL230553B (en) Bispecific antigen binding molecules
LT3378535T (lt) Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
EP3004163A4 (en) Method for purifying antibody
HUE055717T2 (hu) Eljárás antitestek elõállítására
PL2809635T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
FI20125708L (fi) Prosessi hiilivetyjen valmistamiseksi
PT2766331T (pt) Processo para a produção de 2,3,3,3-tetrafluoropropeno
EP2751058A4 (en) PROCESS FOR PRODUCING 2,3,3,3-TETRAFLUOROPROPENE
ZA201307419B (en) Method for producing hydrocarbons
IL239689A0 (en) A method for producing antibodies
PT2773605T (pt) Processo para a produção de 2,3,3,3-tetrafluoropropeno
PL2766330T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
EP2751057A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOROPROPES
AP2013007204A0 (en) Method for producing hydrogenarion catalyst
IL230159A0 (en) Method for the production of 2-amino-5-cyano-n,3-dimethylbenzamide
SG11201402984SA (en) Method for producing pudding
TH1301005419B (th) วิธีการผลิตวัสดุไฮโดรคาร์บอน

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed